Blood Protein Claudin-3 Emerges as a Window Into the Leaky Gut of Adolescents With Functional Digestive Disorders

For millions of teenagers worldwide, recurrent abdominal pain, bloating, constipation, and indigestion are dismissed as growing pains or stress-related complaints. Yet functional gastrointestinal disorders, or FGIDs, account for roughly half of all consultations with pediatric gastroenterologists and impose a heavy toll on quality of life, school attendance, and mental health. Because these conditions lack any visible structural damage or abnormal laboratory findings on conventional tests, clinicians have long struggled to diagnose them objectively, let alone understand what drives them. A new case-control study published in Pediatric Research by a team at Egypt’s National Research Centre now offers a tantalizing clue: a single protein measurable in a routine blood sample may reveal both a breached intestinal barrier and the smoldering inflammation that follows.

The protein in question is claudin-3, a member of the claudin family of transmembrane proteins that zip together the tight junctions sealing the intestinal epithelium. Tight junctions are the molecular gatekeepers of the gut, forming a complex network of epithelial cells interlinked by strands of claudins and other junctional proteins anchored to the actin cytoskeleton. When these seals are intact, the gut selectively absorbs nutrients while excluding luminal antigens, bacterial products, and microbial metabolites. When they fail, the intestine becomes permeable in the colloquial sense of a leaky gut, allowing potentially inflammatory cargo to cross into the underlying mucosal immune system. Claudin-3 is among the most abundantly expressed claudins in the gut and is considered a barrier-forming protein, and circulating claudin-3 in the blood is increasingly regarded as a surrogate readout of intestinal barrier integrity, since disruption of tight junctions can release these proteins into the circulation.

Previous attempts to interrogate the gut barrier in FGIDs have relied almost exclusively on intestinal biopsies, an invasive and impractical approach, particularly in adolescents. The Egyptian team, led by Azza Abd El-Shaheed and colleagues, set out to test whether a simple venous blood draw could accomplish what endoscopy has done in research settings. They enrolled 70 adolescents aged 10 to 18 years who fulfilled the Rome IV diagnostic criteria for FGIDs, confirmed using the Rome IV Diagnostic Questionnaire after detailed history taking and comprehensive clinical evaluation, along with 65 apparently healthy adolescents of comparable age and sex distribution. The researchers deliberately excluded anyone with organic gastrointestinal disease, including celiac disease, inflammatory bowel disease, lactose intolerance, structural anomalies, gastrointestinal infections, chronic hepatic or renal disease, or any acute or chronic inflammatory condition, ensuring that the measured signals could be attributed to functional rather than overt inflammatory pathology.

Using enzyme-linked immunosorbent assays, the team quantified serum claudin-3 alongside four established inflammatory markers: C-reactive protein, interleukin-6, tumor necrosis factor alpha, and haptoglobin. The results were strikingly consistent. Serum claudin-3 concentrations were significantly higher in the FGIDs group than in controls, with a p-value of 0.02. All four inflammatory markers were likewise elevated in the patients: CRP at p = 0.039, interleukin-6 at p = 0.04, tumor necrosis factor alpha at p = 0.021, and haptoglobin at p = 0.001. Taken together, these findings paint a picture of adolescents whose gut barriers are measurably compromised and whose systemic circulation carries the fingerprints of low-grade immune activation, despite the absence of any diagnosable organic disease.

The most conceptually important finding, however, lay in the correlations. Among the FGIDs patients, serum claudin-3 showed significant positive correlations with CRP (r = 0.45, p < 0.001), interleukin-6 (r = 0.30, p = 0.011), and haptoglobin (r = 0.53, p < 0.001). The correlation with tumor necrosis factor alpha, by contrast, did not reach statistical significance (r = 0.19, p = 0.117). This pattern suggests that intestinal barrier dysfunction and systemic low-grade inflammation are not independent phenomena in FGIDs but tightly coupled processes along what the authors describe as a gut-barrier-immune axis. Mechanistically, the hypothesis is coherent: a disrupted epithelial barrier permits translocation of luminal antigens and microbial products across the intestinal wall, activating mucosal and systemic immune responses and driving the release of pro-inflammatory cytokines, which in turn sustain the chronic, subtle inflammation increasingly recognized as a core pathophysiological feature of these disorders.

The selective correlation pattern also carries mechanistic information. Interleukin-6 is the most potent inducer of hepatic acute-phase protein synthesis, including both CRP and haptoglobin, so its tight relationship with claudin-3 may reflect persistent systemic inflammation secondary to barrier impairment. Tumor necrosis factor alpha, on the other hand, is characterized by transient production, a short circulating half-life, and substantial biological variability, any of which could weaken its statistical association with claudin-3 even though patients’ levels were significantly elevated. The authors also acknowledge that the heterogeneous nature of FGIDs and the limited sample size may have contributed to the absence of a significant TNF-alpha correlation, a caveat that applies broadly to biomarker studies in this clinically diverse population.

The new findings dovetail with a growing body of tissue-based research. Kong and colleagues reported altered intestinal expression of claudin proteins in patients with irritable bowel syndrome, while Taki and colleagues demonstrated significantly increased claudin-3 mRNA expression in the duodenal mucosa of patients with functional dyspepsia. Vanheel’s group further showed that disruption of epithelial barrier proteins was associated with increased intestinal permeability and low-grade inflammation in functional dyspepsia. Not all prior studies agree, however: Awad and colleagues detected no significant alterations in claudin-3 expression in colonic biopsies from patients with mixed-type irritable bowel syndrome, and Nojkov and colleagues found no statistically significant difference in claudin-3 gene expression in functional dyspepsia versus controls. The discrepancies likely reflect differences in age groups, specimen types, analytical techniques, FGID subtypes, and disease heterogeneity. What distinguishes the present work is its demonstration that a non-invasive serum assay can capture barrier dysfunction that previously required biopsy.

The clinical implications are considerable. FGIDs are diagnosed today using the Rome IV criteria, which improved characterization and clinical practice but remain insufficient to enable individualized therapy, and no adequate biomarkers exist for precise diagnosis. A validated blood test based on claudin-3 could help stratify patients, track disease activity, and identify those most likely to benefit from therapies aimed at restoring barrier integrity. The authors argue that their findings support the idea that impaired intestinal barrier function may promote the development of FGIDs by inducing inflammation, which in turn positions restoration of intestinal barrier integrity as a potential therapeutic target. If confirmed, interventions ranging from dietary modification to barrier-protective agents could one day be guided by serial claudin-3 measurements rather than symptom reports alone.

Caution is warranted before the laboratory becomes the clinic. This was a cross-sectional case-control study of 135 adolescents from a single outpatient clinic in Cairo, and correlation does not establish causation: elevated claudin-3 could be a cause, a consequence, or merely a correlate of the inflammatory state in FGIDs. The authors themselves recommend further longitudinal studies involving larger cohorts to clarify the role of specific claudin proteins in promoting FGIDs and to evaluate serum claudin-3 as a diagnostic, prognostic, and therapeutic monitoring biomarker. Interventional studies aimed at restoring barrier function are needed to determine whether modulating the barrier actually improves clinical outcomes. Still, the study represents a genuine first: the first assessment of serum claudin-3 as a non-invasive biomarker of intestinal permeability in adolescents with FGIDs. For a disorder group long defined by what it is not, no inflammation, no structural damage, no abnormal tests, the prospect of a measurable molecular signature of a leaky barrier and its inflammatory consequences is a step toward making the invisible visible, and toward treating teenage gut disorders with the biological precision they have long lacked.

Subject of Research: Serum claudin-3 as a non-invasive biomarker of intestinal permeability and low-grade inflammation in adolescents with functional gastrointestinal disorders

Article Title: Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders

Article References: Abd El-Shaheed, A., Mahfouz, N. N., Metwaly, H. H., Sibaii, H., & Abd El-Fattah, S. N. (2026). Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders. Pediatric Research. https://doi.org/10.1038/s41390-026-05497-0

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05497-0

Keywords: claudin-3, intestinal permeability, functional gastrointestinal disorders, leaky gut, tight junctions, adolescents, inflammation, CRP, interleukin-6, TNF-alpha, biomarker, Pediatric Research